FY25 consensus $7.71. Rainer Blair, President and CEO, stated, “Our team executed well to deliver a solid finish to 2025. We were especially pleased with continued strength in Bioprocessing and better-than-expected Life Sciences and Diagnostics revenue in the fourth quarter.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DHR:
- Danaher price target raised to $270 from $260 at TD Cowen
- Danaher price target raised to $250 from $245 at Evercore ISI
- Danaher price target raised to $275 from $250 at Guggenheim
- The Week That Was, The Week Ahead: Macro & Markets, Dec. 20
- Marathon Petroleum CFO John Quaid to depart, Maria Khoury to succeed